FlexFactory is primarily comprised of single-use technologies and associated process hardware and integrated with automation and control components for start-to-finish manufacturing of biopharmaceuticals. Depending on current processes, FlexFactory can reduce carbon dioxide emissions by up to 75 percent and water and energy usage by approximately 80 percent. More information: http://bioprocess.gelifesciences.com/enterprise-solutions/flexfactory/

About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Company’s major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe and its major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com


About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

Back to HCB News

Industry Partnerships Homepage